Scholarlink

Introduction <p>Early treatment for progressive pulmonary fibrosis (PPF) improves outcomes. However, diagnosis of fibrotic-interstitial lung diseases (fibrotic ILDs) and detection of potentially emergent PPF are delayed by 9–12&#xa0;months on average. New ILD diagnostic and PPF monitoring strategies are being investigated to&#xa0;enable early treatment and improve patient outcomes.</p> Methods <p>A time-to-event cost-effectiveness model for reducing delays in ILD diagnosis and PPF detection was developed. Model inputs were obtained from ILD expert clinicians, the literature, and statistical progression equations derived from the INBUILD trial. The study investigated discounted health economic outcomes of early diagnosis of ILD and detection of PPF in eight European countries (Belgium, Denmark, Finland, Greece, Norway, The Netherlands, Portugal, and Sweden).</p> Results <p>The study highlights substantial benefits from reducing the time to diagnose fibrotic ILD and identifying PPF across various ILD subtypes. Clinical advantages arise from any reduction in diagnostic delays, primarily by delaying the onset of PPF and facilitating earlier nintedanib treatment. The model indicates that earlier diagnosis results in quality-adjusted life-year (QALY) gains across all countries, with improvements ranging from 0.061 to 0.084 in the base case. Furthermore, all tested scenarios confirm the cost-effectiveness of early diagnosis of fibrotic ILD and of PPF detection across all studied countries.</p> Conclusion <p>Early diagnosis of ILD and detection of PPF yield cost-effective clinical benefits, supporting the adoption of approaches to speed up ILD diagnosis and PPF detection.</p> Trial Registration <p>ClinicalTrials.gov identifier, NCT02999178.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF)

  • 期刊论文

  • 发表日期：

    2026年5月5日

查看全文
  • Seth H. Walters,
  • Stephane Soulard,
  • Weicheng Ye,
  • Aldo Elsen,
  • Thitima Kongnakorn,
  • Sayooj S. Raj,
  • Pratik Pimple,
  • Pedro G. Ferreira,
  • Antoine Froidure

摘要

Introduction

Early treatment for progressive pulmonary fibrosis (PPF) improves outcomes. However, diagnosis of fibrotic-interstitial lung diseases (fibrotic ILDs) and detection of potentially emergent PPF are delayed by 9–12 months on average. New ILD diagnostic and PPF monitoring strategies are being investigated to enable early treatment and improve patient outcomes.

Methods

A time-to-event cost-effectiveness model for reducing delays in ILD diagnosis and PPF detection was developed. Model inputs were obtained from ILD expert clinicians, the literature, and statistical progression equations derived from the INBUILD trial. The study investigated discounted health economic outcomes of early diagnosis of ILD and detection of PPF in eight European countries (Belgium, Denmark, Finland, Greece, Norway, The Netherlands, Portugal, and Sweden).

Results

The study highlights substantial benefits from reducing the time to diagnose fibrotic ILD and identifying PPF across various ILD subtypes. Clinical advantages arise from any reduction in diagnostic delays, primarily by delaying the onset of PPF and facilitating earlier nintedanib treatment. The model indicates that earlier diagnosis results in quality-adjusted life-year (QALY) gains across all countries, with improvements ranging from 0.061 to 0.084 in the base case. Furthermore, all tested scenarios confirm the cost-effectiveness of early diagnosis of fibrotic ILD and of PPF detection across all studied countries.

Conclusion

Early diagnosis of ILD and detection of PPF yield cost-effective clinical benefits, supporting the adoption of approaches to speed up ILD diagnosis and PPF detection.

Trial Registration

ClinicalTrials.gov identifier, NCT02999178.